Guidance, NICE advice and quality standards In development

Skip to filtersSkip to results

Skip to results

Expected publication date

Expected publication date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme

Showing 1 to 50 of 374

TitleTypeExpected publication date
Melanoma (metastatic) - talimogene laherparepvec [ID508]Technology appraisal guidance
Neuroendocrine tumours (metastatic, unresectable, progressive) - everolimus and sunitinib [ID858]Technology appraisal guidance
Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056]Technology appraisal guidance
Waldenstrom's macroglobulinaemia - ibrutinib [ID884]Technology appraisal guidance
Bevacizumab in combination with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer [ID1145]Technology appraisal guidance
Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243]Technology appraisal guidance
Spartalizumab with dabrafenib and trametinib for untreated BRAF V600 mutation-positive unresectable or metastatic melanoma [ID1668]Technology appraisal guidance
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297Technology appraisal guidance
Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies [ID3845]Technology appraisal guidance
Atogepant for preventing migraine [ID5090]Technology appraisal guidance
Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years (MA review of TA554) [ID6290]Technology appraisal guidance
Selinexor with bortezomib and low-dose dexamethasone for treating relapsed refractory multiple myeloma [ID3797]Technology appraisal guidance
Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy [ID3935]Technology appraisal guidance
Selective internal radiation therapy (SIRT) for neuroendocrine tumours metastatic to the liverInterventional procedures guidance
Endoscopic duodenal mucosal resurfacing for type 2 diabetesInterventional procedures guidance
Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome [ID3947]Technology appraisal guidance
Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over [ID1651]Technology appraisal guidance
Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over [ID5104]Technology appraisal guidance
Harmful gambling: identification, assessment and managementNICE guideline
Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation [ID6198]Technology appraisal guidance
Elranatamab for treating relapsed or refractory multiple myeloma after 3 therapies [ID4026]Technology appraisal guidance
Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (Review of TA611) [ID4069]Technology appraisal guidance
Voxelotor for treating sickle cell disease [ID1403]Technology appraisal guidance
Tirzepatide for managing overweight and obesity [ID6179]Technology appraisal guidance
Tafamidis for treating transthyretin amyloidosis with cardiomyopathy [ID6327]Technology appraisal guidance
Surgical correction of hallux valgus using minimal access techniquesInterventional procedures guidance
Iptacopan for treating paroxysmal nocturnal haemoglobinuria [ID6176]Technology appraisal guidance
Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over [ID3988]Technology appraisal guidance
Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [Review of TA658] [ID4067]Technology appraisal guidance
Selective internal radiation therapy with QuiremSpheres for treating unresectable advanced hepatocellular carcinoma (Partial review of TA688) [ID6376]Technology appraisal guidance
SQ HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (review of TA834) [ID6280]Technology appraisal guidance
Endometriosis: diagnosis and management - diagnosing endometriosisNICE guideline
CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attackDiagnostics guidance
Danicopan as an add-on treatment to a C5 inhibitor for treating extravascular haemolysis in adults with paroxysmal nocturnal haemoglobinuria [ID5088]Technology appraisal guidance
Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]Technology appraisal guidance
Zanubrutinib for treating relapsed or refractory marginal zone lymphoma [ID5085]Technology appraisal guidance
Exagamglogene autotemcel for treating sickle cell disease [ID4016]Technology appraisal guidance
Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments [ID6298]Technology appraisal guidance
Efgartigimod for treating generalised myasthenia gravis [ID4003]Technology appraisal guidance
Ruxolitinib for treating non-segmental vitiligo in people 12 years and over [ID3998]Technology appraisal guidance
Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008]Technology appraisal guidance
Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032]Technology appraisal guidance
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (Review of TA761) [ID5120]Technology appraisal guidance
Eplontersen for treating polyneuropathy caused by hereditary transthyretin amyloidosis [ID6337]Technology appraisal guidance
Faricimab for treating macular oedema caused by retinal vein occlusion [ID6197]Technology appraisal guidance
Teclistamab for treating relapsed or refractory multiple myeloma after 3 treatments (Review of TA869) [ID6333]Technology appraisal guidance
Digital supported self-management technologies for adults with chronic obstructive pulmonary disease: early value assessmentHealth technology evaluation
Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy [ID5100]Technology appraisal guidance
Selpercatinib for advanced thyroid cancer with RET alterations that has not been treated with systemic therapy [ID6132]Technology appraisal guidance
Pembrolizumab with chemotherapy for treating HER2-negative advanced gastric or gastro-oesophageal junction adenocarcinoma [ID4030]Technology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All